German researchers who examined data from Germany, Britain, other European countries and the U.S. found that on a patient basis, the costs for PET and PET/CT procedures are decreasing with the increase in use of the procedures for certain cancers, including nonsmall-cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma and colorectal carcinoma. There still is a need for larger trials to determine the cost-effectiveness of the tests for other cancers, the researchers said.

Full Story:

Related Summaries